oral reversible selective BTK kinase inhibitor

related cmpds in dev. for inflamm. conditions

from rational design of prior crystallized leads

ACS Med. Chem. Lett., Sep. 22, 2020

Bristol Myers Squibb, Princeton, NJ

Structure of BMS-986143, a potent, reversible inhibitor of the Bruton's tyrosine kinase (BTK)

BMS-986143 is a potent, reversible inhibitor of the Bruton’s tyrosine kinase (BTK), which has been successfully targeted by a number of irreversible drugs for oncology. The safety bar is much…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: